Artios is a biotechnology company focused on discovering and developing DDR therapeutics for treating various types of cancers.

Artios

Artios is on a mission to kill cancer by exploiting DNA damage response (DDR) and repair pathways that are leveraged by cancer cells to promote their survival. Our specialized DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR. We have built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications including our ATR inhibitor, ART0380, and our Polθ inhibitor ART6043, as monotherapy and combination treatments. Together with our strategic partnerships with Merck KGaA and Novartis, and research collaborations with premiere institutions like Cancer Research UK, The Institute of Cancer Research, The Netherlands Cancer Institute, and the Crick Institute we are pioneering validated approaches to DDR drug discovery. Visit our website at https://www.artios.com/ for more information about the company and our pipeline.
Artios is based at the Babraham Campus in Cambridge, UK. If you are interested in working at Artios and have the qualities to be part of our team, please submit your application via our website. We are also very mindful of scams that involve recruitment. At this time please note we are currently not working with any third parties in India for recruitment.

Arix Bioscience

iBank

IP Group

EQT life science

Merck Capital Ventures

Andera Partners

Novartis Venture Fund

Pfizer Venture Investments

CaaS Capital Management

RTW Investments

Avidity Partners

Soleus Capital

Tetragon Financial Group Limited

Deep Track Capital

M Ventures

Piper Sandler

Merck

Darmstadt

Artios 

Marco Ranzani (Artios) and Sravanth Hindupur (Novartis) will be presenting the results of the ongoing collaboration between Artios and Novartis in our poster LB222: “Elucidating the cellular responses and mechanisms of action of 177Lu-based radioligand therapy”
The poster presentation will be on Monday April 8th 1.30-5.00 PDT (GMT-7) in Session Late-Breaking Research: Tumor Biology , Poster Section 54, Board Number 17.

The Artios Pharma team will be attending the upcoming American Association of Cancer Research (AACR) Annual Meeting in San Diego, CA. Interested to hear more about DNA damage response (#DDR) pathways and the progress being made with our novel clinical candidates? Graeme Smith, Marco Ranzani and Colleen Sadin will be onsite and available for meetings. 
Contact us at info@artiospharma.com 
#AACR24 #cancerdrugdevelopment  #DNAdamageresponse

We are thrilled and honoured to receive the Cancer Research Horizons - Start-Up Achievement Recognition Award, which was presented to us at the Innovation & Entrepreneurship Awards 2024 ceremony in London last night. 
This award recognises the significant progress we’ve made in our mission to target DNA damage response (#DDR) pathways for #cancerdrugdevelopment in the past 2 years. During that time, we have advanced several DDR products candidates targeting #breastcancer, #ovariancancer and other solid tumours in clinical development as well as presented promising initial clinical data at ESMO. We believe that developing breakthrough cancer treatments that target DDR pathways to specifically destroy certain devastating cancers that are difficult to treat will have a dramatic impact on patients’ lives. 
Thank you, Cancer Research Horizons for recognition of our vision. #oncology #drugdevelopment

At the 2024 DNA Damage, Mutation and Cancer Conference GRC on Monday (March 11), our Vice President of biology, Helen Robinson, will provide an update on the advances being made by Artios Pharma in targeting DNA damage response (#DDR) pathways for #cancerdrugdevelopment. 

In her presentation, Helen will discuss some of the key aspects of early drug discovery and how utilising the Artios DcoDeR platform led to identification of Polθ inhibitors for treating malignant disease while leaving healthy cells intact. #cancerresearch #oncology #drugdevelopment

COM:ARTIOS

Artios

Financials Not Available